字号·· | 护眼
南华早报

康方生物股价暴跌,其抗癌药依沃西单抗遭FDA挫折Akeso shares plummet as Chinese firm’s cancer drug ivonescimab faces FDA setback

点「原文对照」整页切到原文,或双击某段只看那段的原文。

香港上市公司贝达药房的股价周一早盘一度暴跌31.8%,此前美国食品药品监督管理局(FDA)拒绝了其抗癌药物的申请,引发投资者对公司近期商业前景的担忧。

Shares in Hong Kong-listed Akeso plunged as much as 31.8 per cent on Monday morning after the US Food and Drug Administration (FDA) rejected its cancer drug application, raising investor worries over the company’s near-term commercial outlook.

伊沃西单抗是中国涌现出的备受关注的创新药物之一,美国公司Summit Therapeutics周日在一份声明中表示,该药未能确立“实质性有效性证据”,该公司拥有该药在全球市场的独家开发和商业化权利,声明引用了FDA的一封信。

Ivonescimab, one of the most closely watched innovative drugs emerging from China, did not establish “substantial evidence of effectiveness”, said US firm Summit Therapeutics, which has the exclusive rights to develop and commercialise the drug in global markets, in a statement on Sunday, citing a letter from the FDA.

该药物在2024年因在中国一项后期临床试验中击败美国制药巨头默克的Keytruda而声名鹊起。但Summit援引FDA的话称,一项正在进行的全球试验并未显示总体生存期有统计学上的显著改善。

The drug gained prominence in 2024 after beating US pharmaceutical giant Merck’s Keytruda in a late-stage clinical trial in China. But an ongoing global trial did not show a statistically significant improvement in overall survival, Summit quoted the FDA as saying.

总体生存期衡量患者开始治疗后的生存时间,被认为是抗癌药物临床试验中最重要的指标。

Overall survival measures how long patients live after starting treatment and is considered the most important metric in clinical trials for cancer drugs.

虽然此类结果将延长监管不确定性并推迟来自美国的潜在收入,但这不一定会削弱该药物“更长期的美国机遇”,Jefferies亚洲医疗保健研究主管崔崔在一份10月的研究报告中表示。

While such a result would extend regulatory uncertainty and defer potential revenues from the US, it would not necessarily diminish the drug’s “longer-term US opportunity”, said Cui Cui, Jefferies’ head of Asia healthcare research, in an October research note.

鉴于伊沃西单抗在中国创新故事中具有“象征性作用”,此次拒绝可能会“拖累行业情绪”,但这并不代表“对中国来源数据的更广泛拒绝”,崔崔周一补充说。

The rejection could “weigh on sector sentiment” given ivonescimab’s “symbolic role in China’s innovation story”, but it did not represent “a broader rejection of China-originated data”, Cui added on Monday.

伊沃西单抗是一种新型抗癌疗法,可同时阻断肿瘤生存和生长的两个关键通路:程序性死亡蛋白1(PD-1)和血管内皮生长因子(VEGF)。据阿科苏称,这两个通路传统上分别在不同疗法中靶向,将两者结合可提高疗效并减少副作用。

Ivonescimab is a novel cancer therapy that simultaneously blocks two key pathways for tumours to survive and grow: programmed cell death protein 1 (PD-1) and vascular endothelial growth factor (VEGF). Traditionally targeted in separate therapies, combining them improves efficacy and reduces side effects, according to Akeso.

该药物于2024年5月首次获中国国家医疗产品管理局批准。数月后,当阿科苏宣布该药物在降低疾病进展或死亡风险方面几乎减半,超越了全球最畅销的抗癌药物Keytruda时,ivonescimab引起了全球关注。

First approved by China’s National Medical Products Administration in May 2024, ivonescimab drew global attention months later when Akeso announced that it had outperformed Keytruda, the world’s top-selling cancer drug, by cutting the risk of disease progression or death by nearly half.

Keytruda是一种PD-1抑制剂,2025年全球销售额达317亿美元。ivonescimab的试验结果让业界将其誉为生物技术领域的“DeepSeek时刻”,这一说法指代的是2025年1月让全球关注中国人工智能能力的那家人工智能初创公司。

Keytruda, a PD-1 inhibitor, generated US$31.7 billion in global sales in 2025. Ivonescimab’s trial results have led the industry to hail it as biotech’s DeepSeek moment, a reference to the artificial intelligence start-up that brought attention to China’s capabilities in that sector in January 2025.

不过,阿科苏和Summit此后在证明ivonescimab对西方患者的疗效与对中国人群相当方面面临挑战。

Akeso and Summit, however, have since faced challenges in showing that ivonescimab works as well for Western patients as it does for the Chinese population.

在一项正在进行的三期全球试验中,该试验评估ivonescimab联合化疗用于一种非小细胞肺癌患者,去年的早期结果显示,西方患者的总体生存风险比为0.98。这意味着接受该治疗的患者与对照组患者相比,死亡风险仅低2%。

In an ongoing phase three global trial that evaluates ivonescimab combined with chemotherapy in patients with a type of non-small-cell lung cancer, early results last year showed an overall survival hazard ratio of 0.98 for Western patients. This meant that those receiving the treatment had only a 2 per cent lower risk of death compared with patients in a control group.

Summit在6月披露了该正在进行试验的更新数据,将比率提高至0.76。

Summit in June disclosed updated data from the ongoing trial, improving the ratio to 0.76.

虽然FDA并未规定批准所需的特定总体生存风险比,但研究显示,获批的抗癌药物平均比率为0.71。

While the FDA does not mandate a specific overall survival hazard ratio for approval, research shows that approved cancer drugs average a ratio of 0.71.

崔女士周五表示,阿科苏一直在“管理市场预期”,以应对围绕FDA批准的不确定性,此番表态是在美国药监机构做出决定之前。不过,她表示,Summit官网上近期发布的美国销售岗位招聘信息,在一定程度上提振了投资者信心。

Akeso had been “managing market expectations” related to uncertainties surrounding the FDA approval, Cui said on Friday before the US drug regulator’s decision. However, recent postings for US sales roles on Summit’s website had offered a slight boost to investor confidence, she said.

该公司本月早些时候在一份财报中表示,Summit正在同时开展多项ivonescimab临床试验,而该药物在中国已治疗了超过10万名患者。

Summit was simultaneously running several clinical trials for ivonescimab, while the drug had treated more than 100,000 patients in China, the company said in an earnings release earlier this month.

峰会制药公司(Summit)主席罗伯特·达根(Robert Duggan)在周日发表的一份声明中表示,虽然该美国公司“对于在这个环境下等待更多治疗选择的患者及其家属感到失望”,但该公司相信该药物的前景,并决心推进其研发。

While it was “disappointed for patients and their families awaiting additional treatment options in this setting”, the US firm believed in the drug’s prospects and was determined to advance its development, said Summit chairman Robert Duggan in a Sunday statement.

英国药商阿斯利康(AstraZeneca)去年9月宣布,向峰会制药投资20亿美元,承诺共同评估伊沃西妥单抗(ivonescimab)与阿斯利康自身抗癌药物的联合疗法。

British drug maker AstraZeneca announced in September a US$2 billion equity investment in Summit, pledging to jointly evaluate ivonescimab in combination with AstraZeneca’s own cancer drugs.

阅读媒体原文 ↗